Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thymopentin: safety overview.

N Friedmann

    Survey of Immunologic Research
    |January 1, 1985
    PubMed
    Summary

    Thymopentin demonstrates a favorable safety profile, with side effect rates comparable to placebo in clinical trials. This immunomodulator is well-tolerated, even with long-term use and concomitant medications.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.

    The journal of prevention of Alzheimer's disease·2020
    Same author

    Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma.

    Journal of skin cancer·2013
    Same author

    Letter position dyslexia.

    Cognitive neuropsychology·2010
    Same author

    Agrammatism and the psychological reality of the syntactic tree.

    Journal of psycholinguistic research·2001
    Same author

    Tense and agreement in agrammatic production: pruning the syntactic tree.

    Brain and language·1997
    Same author

    Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation.

    Blood·1996

    Area of Science:

    • Immunology
    • Pharmacology
    • Drug Safety

    Background:

    • Thymopentin is a synthetic peptide with immunomodulatory properties.
    • Assessing the safety of novel therapeutic agents is crucial for clinical application.

    Purpose of the Study:

    • To comprehensively review preclinical and clinical safety data for thymopentin.
    • To evaluate the tolerability and side effect profile of thymopentin in patients.

    Main Methods:

    • Review of preclinical safety studies, including ongoing carcinogenicity assessments.
    • Analysis of safety data from 56 patients treated with thymopentin for various conditions.
    • Evaluation of concomitant medication use and adverse event reporting.

    Main Results:

    • Preclinical safety studies are largely complete, with carcinogenicity studies nearing conclusion.
    • Patient data (n=56) show thymopentin is well-tolerated across different doses and administration routes.
    • Adverse event incidence in thymopentin groups was comparable to placebo groups.
    • Thymopentin showed good tolerability when used with other medications.

    Conclusions:

    • Thymopentin exhibits a strong safety profile based on extensive preclinical and clinical data.
    • The compound is well-tolerated in patients, including those on long-term therapy and with concomitant drug use.

    Related Experiment Videos